Award Type [Axis]
Stock Option Plan [Member]
Exercise Price Range [Axis]
Range One [Member]
Options Granted to Employees [Member]
Related Party [Axis]
Lender Warrants [Member]
Underwriter Warrants [Member]
Range Two [Member]
Range Three [Member]
Range Four [Member]
Range Five [Member]
Warrants Issued to Investor Relations Consultant [Member]
Range [Axis]
Minimum [Member]
Maximum [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Customer Relationships [Member]
Trade Name [Member]
State Pharmacy Licenses [Member]
Non-Competition Clause [Member]
Title of Individual [Axis]
Employees [Member]
Income Statement Location [Axis]
Selling and Marketing [Member]
General and Administrative [Member]
Directors [Member]
Consultants [Member]
Patents [Member]
Trademarks [Member]
Restricted Stock Units [Member]
Class of Warrant or Right [Axis]
Warrant [Member]
Equity Components [Axis]
Settlement Warrants [Member]
Placement Agent Warrants [Member]
PIPE Investor Warrants [Member]
Unvested RSUs [Member]
Scenario [Axis]
Initial Payment [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
License Agreement [Member]
Richard L. Lindstrom, M.D [Member]
Second Payment [Member]
Final Payment [Member]
Plens Agreement [Member]
Legal Entity [Axis]
Precision Lens [Member]
Periodic Milestone Payments One [Member]
Periodic Milestone Payments Two [Member]
Periodic Milestone Payments Three [Member]
Periodic Milestone Payments Four [Member]
Periodic Milestone Payments Five [Member]
SightLife Agreement [Member]
Plan Name [Axis]
DED Products [Member]
Securities Purchase Agreements [Member]
Two Accredited Investors [Member]
Sales Agreement [Member]
Cantor Fitzgerald & Co [Member]
Klarity License Agreement [Member]
Eton Pharmaceuticals, Inc. [Member]
Antidilutive Securities [Axis]
Deferred Acquisition Obligations, Convertible Note Payable, Stock Options, Unvested RSUs and Warrants [Member]
Eton License Agreements [Member]
Management Services Agreement [Member]
Asset Purchase Agreement [Member]
Pharmacy Solutions Central, LLC [Member]
Report Date [Axis]
December 31, 2017 [Member]
Stock Purchase Agreement [Member]
Livernois [Member]
Licenses [Member]
SWK Loan Agreement [Member]
July 2017 [Member]
Variable Rate [Axis]
London Inter-Bank Offered Rate [Member]
Livernois & London, LLC [Member]
Warrants [Member]
Long-term Debt, Type [Axis]
Capital Lease Obligations [Member]
2007 Incentive Stock and Awards Plan [Member]
Lender Warrants One [Member]
General And Administrative [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
LSAF Loan [Member]
Financial Instrument [Axis]
Loan Agreement [Member]
SWK Warrants [Member]
Vesting [Axis]
Next Twelve Month [Member]
Imprimis TX [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Filer Category
Entity Common Stock, Shares Outstanding
Trading Symbol
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets
Cash and cash equivalents
Restricted cash and short-term investments
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Current portion of note receivable
Total current assets
Property, plant and equipment, net
Intangible assets, net
Investment in Eton Pharmaceuticals
Note receivable, net of current portion
Goodwill
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
Current portion of deferred acquisition obligation and accrued interest
Current portion of note payable, net of unamortized debt discount
Current portion of capital lease obligations, net of unamortized discount
Total current liabilities
Capital lease obligations, net of current portion and unamortized discount
Deferred acquisition obligation, net of current portion
Accrued expenses, net of current portion
Deferred tax liability
Note payable and paid-in-kind interest, net of unamortized debt discount and current portion
TOTAL LIABILITIES
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 90,000,000 shares authorized, 20,165,561 and 18,627,915 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively
Additional paid-in capital
Accumulated deficit
TOTAL STOCKHOLDERS' EQUITY
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues:
Sales, net
License revenues
Total revenues
Cost of sales
Gross profit
Operating expenses:
Selling and marketing
General and administrative
Research and development
Impairment of long-lived assets
Total operating expenses
Loss from operations
Other income (expense):
Interest expense, net
Debt extinguishment loss
Change in fair value of derivative liabilities
Investment loss from Eton Pharmaceuticals
Gain on deconsolidation of Eton Pharmaceuticals
Loss on sale and disposal of assets
Other income, net
Total other income (expense), net
Loss before income taxes
Income tax benefit, net
Net loss
Basic and diluted net loss per share of common stock
Weighted average number of shares of common stock outstanding, basic and diluted
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment
Amortization of intangible assets
Non-cash gain on contingent acquisition obligation
Deferred income taxes
Amortization of debt issuance costs and discount
Debt extinguishment loss
Paid-in-kind interest added to principal of note payable
Gain on deconsolidation of Eton Pharmaceuticals
Investment loss from Eton Pharmaceuticals
Loss on sale and disposal of assets
Change in fair value of derivative liabilities
Stock-based compensation
Issuance of warrant related to litigation settlement
Changes in assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
NET CASH USED IN OPERATING ACTIVITIES
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds on sale and disposal of assets
Payments on Pharmacy Creations contingent acquisition obligation
Investment in restricted marketable securities
Investment in patent and trademark assets
Purchase of Klarity license
Purchases of property, plant and equipment
NET CASH USED IN INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on capital lease obligations
Net proceeds from public equity offering
Payments on Park deferred acquisition obligation
Proceeds from SWK debt, net of costs
Principal payments, exit fee and other costs of LSAF debt
Proceeds from convertible note payable, net of issuance costs
Proceeds from Essex leaseback, net of issuance costs
Net proceeds from ATM sales of common stock
Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU's
NET CASH PROVIDED BY FINANCING ACTIVITIES
NET CHANGE IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS, beginning of period
CASH AND CASH EQUIVALENTS, end of period
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of embedded conversion feature recorded as debt discount and derivative liability
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering
Reclassification of the fair value of the LSAF warrant from additional paid-in capital to derivative liability
Reclassification of the fair value of the LSAF warrant derivative liability to additional paid-in capital upon closing of the public equity offering
Issuance of common stock and to settle contingent acquisition obligation related to the purchase of PC
Issuance of stock options for consulting services included in accounts payable and accrued expenses
Final fee on note payable recorded as debt discount and included in accrued expenses
Estimated relative fair value of warrants issued in connection with note payable
Purchase of property, plant and equipment included in accounts payable and accrued expenses
Note receivable in connection with sale of assets
Accounting Policies [Abstract]
Description of Business and Basis of Presentation
Summary of Significant Accounting Policies
Related Party Transactions [Abstract]
Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions
Cash and Cash Equivalents [Abstract]
Restricted Cash
Inventory Disclosure [Abstract]
Inventories
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets
Asset Sales And Note Receivable
Asset Sales and Note Receivable
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses
Debt Disclosure [Abstract]
Debt
Leases [Abstract]
Capital Lease Obligation
Equity [Abstract]
Stockholders' Equity and Stock-based Compensation
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Segment Reporting [Abstract]
Segment Information and Concentrations
Subsequent Events [Abstract]
Subsequent Events
Liquidity
Revenue Recognition and Deferred Revenue
Investment in Eton Pharmaceuticals, Inc.
Basic and Diluted Net Loss per Common Share
Recently Adopted Accounting Pronouncements
Recently Issued Accounting Pronouncements
Schedule of Basic Earnings Per Common Share
Schedule of Condensed Income Statement
Schedule of Condensed Balance Sheet
Schedule of Inventories
Schedule of Prepaid Expenses and Other Current Assets
Asset Sales And Note Receivable Tables
Schedule of Future Minimum Payments to Note Receivable
Schedule of Assets and Note Receivable
Schedule of Intangible Assets
Schedule of Amortization Expenses for Intangible Assets
Schedule of Estimated Future Amortization Expense
Schedule of Accounts Payable and Accrued Expenses
Summary of Estimated of Black-Scholes-Merton
Summary of Future Minimum Payments
Schedule of Future Payment Under Capital Lease
Schedule of Stock Option Plan Activity
Schedule of Fair Value Assumption
Schedule of Shares Outstanding and Exercisable
Schedule of Restricted Stock Units Activity
Schedule of Warrants Activity
Schedule of Warrants Outstanding and Warrants Exercisable
Schedule of Stock Based Compensation Granted to Employees Directors Consultants
Statement [Table]
Statement [Line Items]
Net loss
Accumulated deficit
Net cash used in operating activities
Cash resources and restricted investments
Proceeds from wholly owned subsidiary
Number of common stock shares owned
Equity interest percentage
Investment in Eton Pharmaceuticals, Inc.
Equity in loss of Eton Pharmaceuticals
Antidilutive securities
Number of shares vested during the period
Numerator - net loss
Denominator - weighted average number of shares outstanding, basic and diluted
Net income (loss) per share, basic and diluted
Royalty payment percentage on net sales
Payment on issuances of patent
Proceeds from sale of equity securities
Monthly payment
Due from related parties
Ownership percentage
Revenues, net
Loss from operations
Current assets
Total assets
Current liabilities
Stockholders' equity
Total liabilities and stockholders' equity
Money market account
Raw materials
Finished goods
Total inventories
Prepaid insurance
Other prepaid expenses
Deposits and other current assets
Total prepaid expenses and other current assets
Total purchase price
Payment to closing cash amount
Debt interest rate
Debt monthly payment
Debt annual principal payment
Payment term description
Note due amount
Loss on sale of assets
Loss from sale of equipment
Loss on equipment
Sale of stock percentage
Payment of consideration amount
Lease obligation
Asset Sales And Note Receivable - Schedule Of Future Minimum Payments To Note Receivable Details
Remainder of 2017
2018
2019
2020
2021
Total minimum payments
Less: amount representing interest income
Present value of future minimum note receivable
Less: current portion
Note receivable net of current portion
Asset Sales And Note Receivable - Schedule Of Assets Note Receivable Details
Inventories
Furniture and equipment
Asset held for sale
Loss on asset sale
Assets sold
Amortization periods (in years)
Amortization periods description
Cost
Accumulated amortization
Impairment
Net Carrying value
Remainder of 2017
2018
2019
2020
2021
Thereafter
Intangible assets
Accounts payable
Deferred rent
Accrued interest
Accrued exit fee for note payable
Building lease liability
Total accounts payable and accrued expenses
Less: current portion
Non-current total accrued expenses
Debt principal amount
Loss on extinguishment
Loan agreement term
Loan bear interest
Repayment of debt
Debt due date description
Incurred expense debt
Liability of final fee included in accrued expenses
Warrant to purchase of common stock
Warrant exercise price per share
Warrant term
Fair value warrant adjustments
Amortization of debt discount
Weighted-average fair value of warrants granted
Expected terms (in years)
Expected volatility
Risk-free interest rate
Dividend yield
Remainder of 2017
2018
2019
2020
2021
2022
Total minimum payments
Less: amount representing interest
Notes payable, gross (including accrued interest of $251)
Less: unamortized discount
Note payable (including accrued interest of $251), net of unamortized debt discount
Accrued interest
Debt discount amortization
Remainder of 2017
2018
2019
Total minimum lease payments
Less: amount representing interest payments
Present value of future minimum lease payments
Less: unamortized discount
Present value of future net minimum lease payments
Less: current portion, net of unamortized discount
Capital lease obligation, net of current portion and unamortized discount
Stock issued during period, shares, new issues
Price per share
Net proceeds of registered offering
Gross proceeds, percentage
Number of shares issued investor relations related services
Number of shares issued investor relations related services, value
Number of common stock issued for warrant exercises
Proceeds from issuance of warrant
Cash commission, percentage
Sales commission
Available future sales
Issuance of restricted common stock, shares
Closing price of common stock price per share
Stock options granted with exercise price contractual terms
Stock options granted vesting terms
Forfeiture factor, percentage
Unrecognized compensation expense related to unvested stock options granted under the plan
Expense expected to recognize over the weighted-average remaining vesting period
Number of shares, Outstanding, Beginning balance
Number of shares, Options granted
Number of shares, Options exercised
Number of shares, Options cancelled/forfeit
Number of shares, Outstanding, Ending balance
Number of shares, Options exercisable
Number of shares, Options vested and expected to vest
Weighted Avg. Exercise Price, Outstanding, Beginning balance
Weighted Avg. Exercise Price, Options granted
Weighted Avg. Exercise Price, Options exercised
Weighted Avg. Exercise Price, Options cancelled/forfeit
Weighted Avg. Exercise Price, Outstanding, Ending balance
Weighted Avg. Exercise Price, Exercisable Ending Balance
Weighted Avg. Exercise Price, Vested and expected to vest
Weighted Avg. Remaining Contractual Life, Options outstanding
Weighted Avg. Remaining Contractual Life, Options exercisable
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest
Aggregate Intrinsic Value, Options outstanding
Aggregate Intrinsic Value, Options exercisable
Aggregate Intrinsic Value, Options vested and expected to vest
Weighted-average fair value of options granted
Expected terms (in years)
Expected volatility
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Dividend yield
Range of Exercise Prices, minimum
Range of Exercise Prices, maximum
Number of Options Outstanding
Weighted Average Remaining Contractual Life in Years
Weighted Average Exercise Price
Number Exercisable
Weighted Average Exercisable Exercise Price
Number of RSUs unvested, Outstanding, Beginning balance
Number of RSUs granted
Number of RSUs vested
Number RSUs cancelled/forfeit
Number of RSUs unvested, Outstanding, Ending balance
Weighted Average Grant Date Fair Value, Beginning balance
Weighted Average Grant Date Fair Value, RSUs granted
Weighted Average Grant Date Fair Value, RSUs vested
Weighted Average Grant Date Fair Value, RSUs cancelled/forfeit
Weighted Average Grant Date Fair Value, Ending balance
Number of shares, outstanding, beginning balance
Number of shares subject to warrants outstanding, granted
Number of shares subject to warrants outstanding, exercised
Number of shares subject to warrants outstanding, expired
Number of shares, outstanding and exercisable , ending balance
Weighted average remaining contractual life of the outstanding warrants in years
Weighted avg. Exercise price, outstanding, beginning balance
Weighted avg. Exercise price, granted
Weighted avg. Exercise price, exercised
Weighted avg. Exercise price, expired/forfeited
Weighted avg. Exercise price, outstanding and exercisable, ending balance
Issue Date
Warrants Outstanding
Exercise Price
Warrants Exercisable
Expiration Date
Stock based compensation related to equity instruments granted to related parties
Asset purchase, license and commission expense
Royalty payment description
Royalty payments
Net sales
Commission payments, percentage
Number of shares issued during the period
Number of reportable segment
Maximum percentage of sales derived from single customer
Percentage of drug and chemical purchases from three main suppliers
Number of common stock sold
Proceeds from common stock
Accelerated [Member]
Acquisition of Park [Member]
Acquisition of Pharmacy Creations [Member]
Agent Warrant [Member]
Agreement [Axis]
Andrew R Boll [Member]
Baum Performance Option [Member]
Billing And Collection Agreement [Member]
Boll Performance Equity Award [Member]
Consultant
Convertible Senior Note - 2016 [Member]
Deferred Acquisition Obligation And Accrued Interest Current.
Deferred Acquisition Obligation Noncurrent.
Deferred Acquisition Obligations, Stock Options, Unvested RSUs and Warrants [Member]
8.00% Convertible Senior Secured Note [Member]
Embedded Conversion Feature Derivative Liability [Member]
Employees [Member]
Exchange Agreement [Member]
General And Administrative [Member]
Investor Warrants [Member]
John P Saharek [Member]
Lease Agreement [Member]
Lender [Member]
Lender Warrants [Member]
License Agreement [Member]
Life Sciences Alternative Funding LLC [Member]
Liquidity Disclosure [Policy Text Block]
Livernois [Member]
Loan Agreement [Member]
Mark Baum [Member]
Mark L. Baum [Member]
Minimum Revenue Or Cash Balance [Member]
Mr. Boll [Member]
Non Competition Clause [Member]
Non Employee Director [Member]
Note Purchase Agreement [Member]
Notes Payable [Member]
Options granted to employees
Options granted to consultants
Other [Member]
Other Two Thousand FiFteen Acquisitions [Member].
PC [Member]
PIPE Investor Warrants [Member]
Park [Member]
Percentage of drug and chemical purchases from three main suppliers.
Pharmacy Creations Llc [Member].
Placement Agent Warrants [Member]
Purchase of furniture and equipment included in accounts payable and accrued expenses.
Range five [member]
Range four [member].
Range one [member].
Range three [member].
Range two [member].
Recently Adopted Accounting Pronouncements [Policy Text Block]
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering.
Accumulated Deficit [Member]
Sales Agreement [Member]
Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block].
Schedule of warrants outstanding and exercisable [Table Text Block]
Securities Purchase Agreement [Member]
Sellers [Member]
Selling And Marketing [Member]
Senior Note - 2015 [Member]
Settlement Warrants [Member]
Share Based Compensation Award Tranche Five [Member]
Share Based Compensation Award Tranche Four [Member]
Stock Option One [Member]
StockOptionPlanMember
Third Party [Member]
2007 Incentive Stock and Awards Plan [Member]
Underwriter Warrants [Member].
Underwriting Agreement [Member]
unvested RSUs [Member]
Urigen Pharmaceuticals Inc [Member]
Warrant Derivative Liability [Member]
Warrant One [Member]
Warrant Three [Member]
Warrant Two [Member]
Warrants Issued To Investor Relations Consultant One [Member]
Royalty payment description.
Initial Payment [Member]
Second Payment [Member]
Final Payment [Member]
Richard L. Lindstrom, M.D [Member]
Commission payments, percentage.
Plens Agreement [Member]
Precision Lens [Member]
SightLife Agreement [Member]
ASED Products [Member]
Periodic Milestone Payments One [Member]
Periodic Milestone Payments Two [Member]
Periodic Milestone Payments Three [Member]
Periodic Milestone Payments Four [Member]
Periodic Milestone Payments Five [Member]
Finite Lived Intangible Assets Impairment.
Building Lease Liability.
Securities Purchase Agreements [Member]
Two Accredited Investors [Member]
Cantor Fitzgerald & Co [Member]
2007 Incentive Stock and Awards Plan [Member]
Net proceeds of registered offering.
Gross proceeds, percentage.
Cash commission, percentage.
Closing price of common stock price per share.
Forfeiture factor, percentage.
Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.
Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.
Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.
Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.
Share based compensation arrangements by share based payment award non options expirations in period weighted average exercise price.
Warrants issuance date.
Warrants exercisable.
Warrants expiration date.
Stock Purchase Agreement [Member]
Klarity License Agreement [Member]
Issuance of common stock and to settle contingent acquisition obligation related to the purchase of PC.
Non-cash gain on contingent acquisition obligation.
Eton Pharmaceuticals, Inc. [Member]
Deferred Acquisition Obligations, Convertible Note Payable, Stock Options, Unvested RSUs and Warrants [Member]
Warrants [Member]
Stock Options [Member]
Royalty payment percentage on net sales.
Eton License Agreements [Member]
Payment on issuances of patent.
Management Services Agreement [Member]
Asset Purchase Agreement [Member]
Pharmacy Solutions Central, LLC [Member]
Payment to closing cash amount.
December 31, 2017 [Member]
Livernois [Member]
Disposal Group, Including Discontinued Operation, Assets, Loss on Assets for sale.
Licenses [Member]
State Pharmacy Licenses [Member]
Note Payable [Member]
SWK Loan Agreement [Member]
July 2017 [Member]
London Inter-Bank Offered Rate [Member]
Warrant term.
Number of common stock issued for warrant exercises.
Issuance of warrant related to litigation settlement.
Purchase of license.
Final fee on note payable recorded as debt discount and included in accrued expenses.
Note receivable in connection with sale of assets.
Schedule of Assets and Note Receivable [Table Text Block]
Asset Sales and Note Receivable [Text Block]
Available future sales.
Lender Warrants One [Member]
LSAF Loan [Member]
SWK Warrants [Member]
Next Twelve Month [Member]
Imprimis TX [Member]
Assets, Current
Liabilities, Current
Liabilities
Revenue, Net
Health Care Organization, Medical Supplies and Drugs Expense
Gross Profit
Operating Costs and Expenses
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Income Tax Expense (Benefit)
Gain (Loss) on Disposition of Assets
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Increase (Decrease) in Employee Related Liabilities
Increase (Decrease) in Customer Deposits
Net Cash Provided by (Used in) Operating Activities
Payment for Contingent Consideration Liability, Investing Activities
Payments to Acquire Intangible Assets
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Repayments of Debt and Capital Lease Obligations
Payments of Financing Costs
Net Cash Provided by (Used in) Financing Activities
Inventory Disclosure [Text Block]
Operating Leases, Future Minimum Payments Receivable
Disposal Group, Including Discontinued Operation, Inventory, Current
Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Net
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year
Finite-Lived Intangible Assets, Amortization Expense, Year Two
Finite-Lived Intangible Assets, Amortization Expense, Year Three
Finite-Lived Intangible Assets, Amortization Expense, Year Four
Finite-Lived Intangible Assets, Amortization Expense, Year Five
Accounts Payable and Accrued Liabilities
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year
Operating Leases, Future Minimum Payments, Due in Two Years
Operating Leases, Future Minimum Payments, Due in Three Years
Operating Leases, Future Minimum Payments, Due in Four Years
Operating Leases, Future Minimum Payments, Due in Five Years
Operating Leases, Future Minimum Payments Due
Accrued Liabilities, Current
Capital Leases, Future Minimum Payments, Remainder of Fiscal Year
Capital Leases, Future Minimum Payments Due in Two Years
Capital Leases, Future Minimum Payments Due in Three Years
Capital Leases, Future Minimum Payments Due
Capital Leases, Future Minimum Payments, Interest Included in Payments
Capital Leases, Future Minimum Payments, Net Minimum Payments
Debt Instrument, Unamortized Discount
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1